Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNFRSF1A | P19438 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | ESRRA | P11474 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.41 |
| ▸ | RARG | P13631 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | RARA | P10276 | 1/20 | 0.40 |
| ▸ | RARB | P10826 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CA5A | P35218 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | RXRA | P19793 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1187957 | 0.89 | LMNA (0.46) | TNFRSF1ALMNAESRRAALDH1A1TDP1 | |
| SCHEMBL2124314 | 0.88 | TPMT (0.46) | TNFRSF1ALMNAESRRAPTGS2RARG | |
| SCHEMBL1728715 | 0.88 | TNFRSF1A (0.43) | TNFRSF1ALMNAESRRARARGALDH1A1 | |
| SCHEMBL2123278 | 0.88 | ALDH1A1 (0.46) | TNFRSF1ALMNAESRRARARGALDH1A1 | |
| SCHEMBL1730810 | 0.85 | TNFRSF1A (0.42) | TNFRSF1ALMNAESRRAPTGS2RARG | |
| SCHEMBL3637333 | 0.84 | TNFRSF1A (0.56) | TNFRSF1APTGS2RARGRARARARB | |
| SCHEMBL5677096 | 0.82 | TNFRSF1A (0.51) | TNFRSF1ALMNAPTGS2ALDH1A1TSHR | |
| SCHEMBL3579165 | 0.82 | TNFRSF1A (0.51) | TNFRSF1APTGS2ALDH1A1TSHRTDP1 | |
| SCHEMBL1730836 | 0.82 | ALDH1A1 (0.55) | TNFRSF1ALMNAALDH1A1TSHRTDP1 | |
| SCHEMBL12187796 | 0.81 | LMNA (0.40) | TNFRSF1ALMNAESRRARARGRARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102382037-B | Phenylpropionic acid compound and method for making thereof and pharmaceutical use | INSTITUTE OF MATARIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2016-01-20 | — | — | CN | disclosed |
| CN-102382037-A | Benzene propanoic acid compound and preparation method and medicine use thereof | INST MATERIA MEDICA CAMS | 2012-03-21 | — | — | CN | disclosed |
| US-20110059970-A1 | 4-PHENYL-1,3-THIAZOLES AND 4-PHENYL-1,3-OXAZOLES DERIVATIVES AS CANNABINOID RECEPTOR LIGANDS | IPSEN PHARMA S.A.S. (FR) | 2011-03-10 | — | — | US | disclosed |
| EP-2201007-A1 | CANNABINOID RECEPTOR LIGANDS | IPSEN PHARMA S.A.S. (FR) | 2010-06-30 | — | — | EP | disclosed |
| WO-2009071753-A1 | CANNABINOID RECEPTOR LIGANDS | IPSEN PHARMA S.A.S. (FR) | 2009-06-11 | — | — | WO | disclosed |
| WO-2008052288-A1 | DITHIOLE COMPOUNDS AS COX INHIBITORS | NEURO THERAPEUTICS LIMITED (AU) | 2008-05-08 | — | — | WO | disclosed |
| US-7232812-B2 | Substituted azetidine compounds, their preparation and use as medicaments | LABORATORIOS DE DR. ESTEVE S.A. (ES) | 2007-06-19 | — | — | US | disclosed |
| US-20070093469-A1 | Substituted azetidine compounds as cyclooxygenase-1-cyclooxygenase-2 inhibitors, and their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE S.A (ES) | 2007-04-26 | — | — | US | disclosed |
| CN-1121374-C | Novel trienoic retinoid compounds and method | LIGAND PHARMACEUTCALS INC (US) | 2003-09-17 | — | — | CN | disclosed |
| US-6083977-A | HAVING ACTIVITY FOR RETINOIC ACID RECEPTORS AND RETINOID X RECEPTORS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2000-07-04 | — | — | US | disclosed |
| EP-0800503-B1 | NOVEL TRIENOIC RETINOID COMPOUNDS AND METHODS | LIGAND PHARM INC (US) | 2000-05-10 | — | — | EP | disclosed |
| CN-1220656-A | Novel trienoic retinoid compounds and method | LIGAND PHARM INC (US) | 1999-06-23 | — | — | CN | disclosed |
| US-5721103-A | SKIN DISORDERS; VISION DEFECTS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1998-02-24 | — | — | US | disclosed |
| EP-0800503-A1 | NOVEL TRIENOIC RETINOID COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS, INC. (US) | 1997-10-15 | — | — | EP | disclosed |
| WO-1996020913-A1 | NOVEL TRIENOIC RETINOID COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1996-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059970-A1 | 4-PHENYL-1,3-THIAZOLES AND 4-PHENYL-1,3-OXAZOLES DERIVATIVES AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, NPY1R | TNFRSF1A 1304/4885LMNA 2448/4885ESRRA 577/4885 |
| US-20070093469-A1 | Substituted azetidine compounds as cyclooxygenase-1-cyclooxygenase-2 inhibitors, and their preparation and use as medicaments | PTGS1, PTGS2, PTGES2 | TNFRSF1A 1937/4885LMNA 4245/4885ESRRA 3410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.